© 2024
NPR News, Colorado Stories
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
KUNC's primary signal, 91.5, will experience periodic outages and periods of low power operation on Wednesday, Sept. 11 from 9 a.m. to 5 p.m. This is due to transmission tower maintenance. We apologize for the inconvenience.

The FDA Just Approved A Major Alzheimer’s Drug. Now What?

Biogen is the maker of aducanumab, which has been the source of much debate amongst Alzheimer's experts.
Biogen is the maker of aducanumab, which has been the source of much debate amongst Alzheimer's experts.

On Monday, the FDA approved aducanumab, a new medication for Alzheimer’s.

It’s the first new drug for the disease in almost two decades and the first to attack the disease process itself, instead of just its symptoms.

But the FDA’s approval comes despite an intense debate over the drug’s efficacy and associated side effects.

From Kaiser Health News:

We discuss what we know about aducanumab and how it will shape the future of Alzheimer’s research and treatment.

Copyright 2021 WAMU 88.5

Tags
Kathryn Fink
Kathryn Fink is a producer with NPR's All Things Considered.